BioMedNewsBreaks — Caring Brands, Inc. (NASDAQ: CABR) Closes $4 Million Offering as Company Uplists to Nasdaq Capital Market

Caring Brands (NASDAQ: CABR) closed its underwritten U.S. public offering of 1,000,000 shares of common stock at $4.00 per share for gross proceeds of about $4 million before underwriting discounts and expenses, completing the Company’s uplisting to the Nasdaq Capital Market, where its shares began trading on Nov. 13, 2025. Caring Brands granted the underwriter a 45-day option to purchase up to 150,000 additional shares and intends to use net proceeds for general working capital, marketing and sales of its proprietary products, and repayment of certain debt.

To view the full press release, visit https://ibn.fm/y2EXR

About Caring Brands, Inc.

Caring Brands is a wellness consumer products company who offers several over-the-counter (OTC) and cosmetic consumer products. The Company’s product pipeline includes a diverse range of products, such as hair loss treatments, eczema and psoriasis treatments, vitiligo solutions, and a jellyfish sting protective suncare line catering to diverse health and wellness needs. The Company’s method of operation ensures that the mechanism of action of all products is established, efficacy is determined through controlled clinical trials, products are protected by issued and filed patents, and products have acceptable commercial stability.

More information about the company can be found at https://caringbrands.com/

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW
Breaks Categories: News

Recent Posts

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Builds Scalable Business Through Vertical Integration, Dual-Market Strategy

Earth Science Tech (OTC: ETST) is building a scalable, self-sustaining healthcare business through strategic acquisitions, end-to-end…

3 days ago

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Seeks to Redefine Knee Cartilage Repair with Resorbable Hydrogel Technology

Regentis Biomaterials (NYSE American: RGNT) is developing GelrinC, an acellular hydrogel implant designed to shift knee…

3 days ago

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing

VERAXA Biotech (NASDAQ: VRXA) , a developer of next-generation antibody-based cancer therapies, provided an update…

5 days ago

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial

Quantum BioPharma (NASDAQ: QNTM) entered into a Study Start-Up Agreement (“SUA”) with the clinical research…

6 days ago

BioMedNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Reports Positive Interim Phase 2 Data for ENV-105 in Prostate Cancer

Kairos Pharma (NYSE American: KAPA) announced positive interim efficacy data from its ongoing Phase 2…

6 days ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Opens BIO REBOOT Registration, Announces PDAOAI Presentations at Drug Discovery 2026 

Oncotelic Therapeutics (OTCQB: OTLC), together with its wholly owned subsidiary Pet2DAO, Inc., announced that its…

7 days ago